Data from several studies suggest that tachykinins mayplay an important role in the pathophysiology of airway diseases, especially asthma. Wehad a screening program for selective tachykinin antagonists of microbial products origin. In the previous papers we described the discovery and characterization of WS9326, FK224X'2) and actinomycin D3) as tachykinin antagonists. We screened them for activity in a receptor binding assay to tachykinin receptors on guinea-pig lung membraneand for inhibition of the neurokinin A (NKA)-induced guinea-pig tracheal contractile response. In this paper we report on cyclosporin C (WF3484) as an inhibitor of substance P (SP)-induced platelet aggregation, and on the receptor binding properties of cyclosporin C, actinomycin D, WS9326 and FK224 for human tachykinin receptor subtypes in transfected mammaliancells.
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Kenichi Hayashi, Motoaki Nishikawa* , Ichiro Aramori, Sumio Kiyoto and MasakuniOkuhara Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 5-2-3 Tokodai, Tsukuba City, Ibaraki 300-26, Japan (Received for publication June 27, 1995) Data from several studies suggest that tachykinins mayplay an important role in the pathophysiology of airway diseases, especially asthma. Wehad a screening program for selective tachykinin antagonists of microbial products origin. In the previous papers we described the discovery and characterization of WS9326, FK224X'2) and actinomycin D3) as tachykinin antagonists. We screened them for activity in a receptor binding assay to tachykinin receptors on guinea-pig lung membraneand for inhibition of the neurokinin A (NKA)-induced guinea-pig tracheal contractile response. In this paper we report on cyclosporin C (WF3484) as an inhibitor of substance P (SP)-induced platelet aggregation, and on the receptor binding properties of cyclosporin C, actinomycin D, WS9326 and FK224 for human tachykinin receptor subtypes in transfected mammaliancells. guinea-pig tracheal constriction were carried out as described previously1j2). As shown in Fig. 1 SP produced a platelet aggregation in a dose dependent manner and stable aggregation occured at levels above 4 x 10~7 m SP. NKAalso produced the platelet aggregation in a dose dependent manner (data not shown). WF3484(cyclosporin C) exhibited the inhibitory activities for the platelet aggregation induced by SP (2x 10"6m) and NKA (2x 10"6m)withtheIC50 values 5.0x 10"7mand 
IC50(M) :
Agonist Cyclosporin C Actinomycin D WS9326A FK224 SP (1.0x10-10M) 7.47x10"7 >5.00x10"4 2.00x10"6 1.23x10"7 NKA(1.0x10"10M) 1.89x10"6 3.01 x10"6 5.71 x10"7 2.37x10"7 1.7 x 10"6m, respectively. On the other hand WF3484 (cyclosporin C) was inactive against for the platelet aggregation induced by 2 x 10"6m ofADP ( Table 1) . The transfection and functional expression of CDNA clones for single receptor subtypes in the separate cell lines are useful for characterization of tachykinin antagonist. Chinese hamster ovary (CHO) (dhfr") cells that were transfected with the human NKXand NK2
receptors and stably expressing cell lines were established for radioligand binding studies. Clonal cells expressing the humanNKtreceptor have been described previously6). A clonal cell line expressing the human NK2 receptor was established according to the procedures described previously6). Clonal cells were maintained in a minimal essential medium" lacking ribonucleosides and deoxyribonucleosides and supplemented with 10%dialyzed fetal bovine serum. Membranepreparation of receptorexpressing cells was performed as described previously7). The nonspecific binding was defined as the binding activity in the presence of 3.2jum of the corresponding unlabeled tachykinin and was subtracted from the total binding activity for determination of the specific binding.
The radioactivity was counted in a gamma counter (Packard Auto Gamma Model 5650). The results obtained in these experiments are summarized in Table   2 . Cyclosporin C was active against human NK-1and NK-2 receptors, although the affinity for human NK-1 receptor is slightly higher than that for the human NK-2
receptor. FK224 was a selective NK-1, NK-2 dual antagonist, and was equipotent for both the guinea-pig and humanreceptors. Onthe contrary actinomycin D showed highly selective for guinea-pig and human NK-2 receptors.
In Tables 1 and 2 , the various anti-tachykinin activities we obtained with these fermentation products are compared. Cyclosporin C exhibited about a 3-fold difference between platelet aggregation inhibition and binding affinity for human NK-1 and NK-2 receptors. FK224 has a higher affinity for human NK-1 and NK-2 receptors and it has been reported that FK224 acts as NK-1,2 dual receptor antagonist in vitro and in v/v6>2'9'10). Present data demonstrated that actinomycin D is highly selective for the human NK-2 receptor and it has been reported that actinomycin D act as NK-2specific receptor antagonist in vitro and in vivo3). Cyclosporin C was a potent inhibitor of platelet aggregation induced by SP and NKA and also was active against guinea-pig NK-1receptor. As shown in Table 2 , cyclosporin C was an NK-1, NK-2 dual receptor antagonist. However,against our expectation, cyclosporin C has no effect on tracheal constrictions produced by SP and NKA. We tried receptor binding for SP using platelet membrane fractions, and observed a small amount of specific binding of SP to the platelet membranes.So we could not confirm the half-maximal concentration (IC50) of cyclosporin C to inhibit specific binding of platelet SP receptors. Detailed mechanisms and actions for the tachykinin inhibition of cyclosporin C are to be studied further. However, it was observed in the present investigation that platelets express the tachykinin receptors on the platelet cell surface.
